InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: EndoTarget post# 243940

Sunday, 11/29/2015 9:46:39 AM

Sunday, November 29, 2015 9:46:39 AM

Post# of 345733
Another interesting twist as Peregrine moves forward. Normally, why would anyone think otherwise about a simple job transfer.... except when it is anyone that has to do with the advancement of Peregrine Pharmaceuticals. We will have to wait and see if PPHM pops up in the Janney shelf

it was easier to lure over Debjit Chattopadhyay and gain any advantage possible with info related to PPHM, especially when Piper Jaffray private clients get an early glimpse of what is hot in biotech

https://www.tipranks.com/analysts/debjit-chattopadhyay

Experience
Managing Director
Janney Montgomery Scott LLC
November 2015 – Present (1 month)

Biotechnology Equity Research
Senior Equity Research Analyst
Roth Capital Partners
April 2014 – November 2015 (1 year 8 months)Greater New York City Area

ROTH Capital Partners | Financing Innovation | Investment Banking, Orange County, CA

ROTH Capital Partners | Financing Innovation | Investment Banking, Orange County, CA

..
..
https://www.linkedin.com/in/debjit-chattopadhyay-0247536

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News